{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:12Z","timestamp":1786512492769,"version":"build-2736575974"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gray-zone lymphoma (GZL) is a rare and biologically distinctive B-cell lymphoma that exhibits overlapping clinical and pathological features between classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (PMBL). Mediastinal Gray-zone lymphoma (MGZL) occurring as a second primary malignancy following treatment for cHL is exceedingly rare, and both its pathogenesis and optimal clinical management remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 22-year-old woman diagnosed with cHL in 2020 achieved complete remission after ABVD chemotherapy. Five years later, a new mediastinal mass was identified during routine follow-up. Excisional biopsy via video-assisted thoracoscopic surgery (VATS), together with comprehensive immunohistochemical and molecular analyses, confirmed a diagnosis of secondary MGZL. The patient subsequently underwent salvage chemotherapy followed by autologous stem-cell transplantation, achieving clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In long-term survivors of cHL, the emergence of a new mediastinal mass necessitates repeat biopsy and precise pathological reassessment rather than presumption of relapse. Second primary lymphomas, such as MGZL, require individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1913997","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:43:05Z","timestamp":1786509785000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Second primary mediastinal grey-zone lymphoma following treatment for classical Hodgkin lymphoma: a rare case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuan","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Pathology, Tongde Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongde Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongde Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongde Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongde Hospital of Zhejiang Province","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2024.09.006","article-title":"translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma","volume":"49","author":"Lorente Fern\u00e1ndez","year":"2025","journal-title":"Farm Hosp"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3239","article-title":"Classic hodgkin lymphoma","volume":"42","author":"Kahn","year":"2024","journal-title":"Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3131","article-title":"Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population","volume":"41","author":"N\u00fa\u00f1ez-Garc\u00eda","year":"2023","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000748C","article-title":"All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents","volume":"2025","author":"Sarkozy","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10121019","article-title":"Hodgkin Reed-Sternberg-like cells in non-Hodgkin lymphoma","volume":"10","author":"Parente","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ajcp\/aqab122","article-title":"How I diagnose primary mediastinal (thymic) large B-cell lymphoma","volume":"156","author":"Ondrejka","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030742","article-title":"The grey zones of classic Hodgkin lymphoma","volume":"14","author":"Bosch-Schips","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03550-5","article-title":"Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology","volume":"483","author":"Gibson","year":"2023","journal-title":"Virchows Arch"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1254256","article-title":"Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report","volume":"13","author":"Asrani","year":"2024","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:43:23Z","timestamp":1786509803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1913997"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1913997","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1913997"}}